DS
ADAP

David Shaw’s Adaptimmune Therapeutics ADAP Stock Holding History

David Shaw’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,579
Closed -$40K – 3929
2019
Q3 		$40K Sell
26,579
-51,411
-66% -$120K ﹤0.01% 3736
2019
Q2 		$314K Sell
77,990
-216,583
-74% -$883K ﹤0.01% 3299
2019
Q1 		$1.27M Buy
294,573
+80,412
+38% +$374K ﹤0.01% 2462
2018
Q4 		$1.23M Buy
+214,161
New +$1.58M ﹤0.01% 2517
2018
Q2 		– Sell
-31,367
Closed -$352K – 3668
2018
Q1 		$352K Sell
31,367
-50,253
-62% -$440K ﹤0.01% 3067
2017
Q4 		$545K Sell
81,620
-119
-0.1% -$919 ﹤0.01% 2934
2017
Q3 		$669K Buy
81,739
+46,243
+130% +$289K ﹤0.01% 2745
2017
Q2 		$159K Sell
35,496
-56,371
-61% -$295K ﹤0.01% 3224
2017
Q1 		$506K Sell
91,867
-8,656
-9% -$37.9K ﹤0.01% 2730
2016
Q4 		$407K Buy
100,523
+18,216
+22% +$87.4K ﹤0.01% 2968
2016
Q3 		$580K Buy
82,307
+71,177
+640% +$543K ﹤0.01% 2718
2016
Q2 		$91K Sell
11,130
-702
-6% -$6.61K ﹤0.01% 3263
2016
Q1 		$96K Buy
+11,832
New +$96.8K ﹤0.01% 3286
2015
Q3 		– Sell
-15,232
Closed -$279K – 3697
2015
Q2 		$279K Buy
+15,232
New +$261K ﹤0.01% 3444

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

David Shaw's ADAP Position: Q4 2019 in Review

David Shaw sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 26,579 shares — an estimated $40K sold.

David Shaw first reported a position in ADAP in Q2 2015 and held it in 14 quarters. The position peaked at $1.27M in Q1 2019. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

  • David Shaw reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • David Shaw sold 26,579 Adaptimmune Therapeutics shares in Q4 2019, an estimated $40K.
  • David Shaw first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 14 quarters.
  • David Shaw's Adaptimmune Therapeutics position peaked at $1.27M in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.